MAGE-A3 Antigen-Specific Cancer Immunotherapeutic in Patients With Progressive Metastatic Cutaneous Melanoma
Clinical trial NCT00706238 · TERMINATED
Trial details
- NCT number
- NCT00706238
- Sponsor
- GlaxoSmithKline
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2008-09-29
- Primary completion
- 2011-01-19
- Enrollment
- 5
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.